Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.32 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.31 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.31 |
| ▸ | CDK1 | P06493 | 3/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.31 |
| ▸ | CDK2 | P24941 | 3/20 | 0.31 |
| ▸ | CDK9 | P50750 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048670 | 0.77 | FGFR3 (0.44) | PDK2CNR2FGFR3KDRAXL | |
| SCHEMBL31048672 | 0.77 | FGFR3 (0.44) | PDK2CNR2FGFR3KDRAXL | |
| SCHEMBL31048657 | 0.75 | ERN1 (0.44) | PDK2IRAK4CSF1RCNR2FGFR3 | |
| SCHEMBL14895579 | 0.74 | ERN1 (0.42) | PDK2 | |
| SCHEMBL21415683 | 0.74 | ERN1 (0.42) | PDK2 | |
| SCHEMBL14895580 | 0.74 | ERN1 (0.42) | PDK2 | |
| SCHEMBL24070129 | 0.73 | L3MBTL1 (0.44) | — | |
| SCHEMBL30369635 | 0.73 | L3MBTL1 (0.44) | — | |
| SCHEMBL28974293 | 0.73 | L3MBTL1 (0.44) | — | |
| SCHEMBL25910894 | 0.73 | L3MBTL1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662204-A2 | TELOMERASE INHIBITOR COMPOUNDS | Geron Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20240343713-A1 | TELOMERASE INHIBITOR COMPOUNDS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2024-10-17 | — | — | US | disclosed |
| WO-2024168165-A2 | TELOMERASE INHIBITOR COMPOUNDS | GERON CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343713-A1 | TELOMERASE INHIBITOR COMPOUNDS | TERT, POT1, TERF2 | PDK2 1916/4885IRAK4 2052/4885CSF1R 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.